

Key Idefirix Market Trend 2025-2034: Growing Innovation In Desensitization Treatments For Sensitized Kidney Transplant

The Business Research Company's Idefirix Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, January 27, 2025
/EINPresswire.com/ -- Is the Idefirix Market Set to Witness Substantial Growth?

In recent years, the iderfix market has significantly grown due to several contributing factors. The market size is trending upwards at an impressive compound annual growth rate CAGR. This growth trajectory is expected to carry the market from a valuation of several millions in 2024 to a formidable total by 2025.



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!"

The Business Research Company

What is contributing to this upward trend?

The answer lies in increased incidences of allergic diseases, increased doses of the drug, a rise in the prevalence of chronic diseases, heightened demand for organ transplants, and a spike in both the prevalence and incidence of kidney diseases.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20093&type=smp>

[px?id=20093&type=smp](https://www.thebusinessresearchcompany.com/sample.aspx?id=20093&type=smp)

From 2025 onwards, the iderfix market is projected to maintain its growth momentum. It is estimated to continue expanding, reaching another peak by 2029. Several factors can be attributed to this forecasted surge. Upcoming trends include advancements in antibody-cleaving enzyme technology, growing investments in transplant immunology research, collaborations with transplant centers for clinical integration, and a more focused move towards personalized medicine. These are coupled with government initiatives for organ transplantation, rising awareness of antibody-mediated rejection, and an increase in research and development



The Business
Research Company

The Business Research Company

efforts.

Central to the growth of the idefirix market is the rising prevalence and incidence of kidney diseases. As this escalates, so does the demand for idefirix, an innovative immunoglobulin G IgG-degrading enzyme therapy. This groundbreaking therapy successfully enables kidney disease patients to undergo life-saving transplants by effectively reducing the donor-specific antibodies that would ordinarily cause rejection.

For instance, in June 2023, a UK-based research group published a report projecting that the incidence of acute kidney injury would increase from an estimated 615,000 cases in 2022 to 637,000 by 2033. Based on such significant statistics, the increasing prevalence and incidence of kidney diseases are undeniably responsible for the idefirix market's robust growth.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/idefirix-global-market-report>

Who Are The Key Players In The idefirix Market?

The market's scope extends to key industry players, including Hansa Biopharma AB, a global leader in the idefirix industry. This biopharmaceutical company is consistently working towards creating a vigorous presence in the global idefirix market.

Furthermore, the idefirix market is embracing innovative solutions, specifically desensitization treatments. This medical procedure reduces or removes harmful antibodies, enabling transplant patients to receive organs from incompatible donors. In July 2023, Hansa Biopharma announced that Australia's Therapeutic Goods Administration TGA approved its idefirix drug as a desensitization treatment for highly sensitized kidney transplant patients. This marks a significant stride in developing kidney transplant options for highly sensitized patients in Australia.

How Is The idefirix Market Segmented?

Diving deeper into the idefirix market segmentation, the report covers four primary sectors:

- 1 By Patient Demographics: Pediatric Patients, Adult Patients
- 2 By Application: Kidney Transplantation, Desensitization Protocols
- 3 By End-User: Hospitals, Specialized Clinics, Home Healthcare
- 4 By Distribution Channel: Direct Sales, Pharmacies

In terms of geography, Europe was the largest region in the idefirix market as of 2024. However, the region is expected to experience the fastest growth in the forecast period, followed by Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse for more similar reports-

Peptide Therapeutics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report>

Bipolar Disorder Therapeutics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report>

Neurodegenerative Disorder Therapeutics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report>

Take a closer look at the dynamic idefirix market with more similar reports provided by The Business Research Company. With over 15000+ reports across 27 industries and 60+ geographies, The Business Research Company has established a reputation for comprehensive, data-rich research and insights. Drawing upon 1,500,000 datasets, in-depth secondary research, and key insights from industry leaders, you can garner the information you need to stay ahead.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/780650952>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.
© 1995-2025 Newsmatics Inc. All Right Reserved.